Exavir Therapeutics Inc.
Publicly observedSan Francisco, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | San Francisco | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Exavir Therapeutics Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | EV9JGJL7VVF9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant4 Aug 2026Publicly observed
NIH SBIR/STTR award: Development of an Ultra-Long-Acting, Self-Administered, Dolutegravir-Based Treatment Regimen for HIV-1 and HIV-HBV Co-infection
USD 998,034.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant17 Aug 2023Publicly observed
NIH SBIR/STTR award: XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.